UBS raised the firm’s price target on Teva (TEVA) to $26 from $23 and keeps a Buy rating on the shares. The stock can continue to see a relief rally as the Austedo IRA price gets revealed by November 30 or earlier, the analyst tells investors in a research note. Payor insights suggest that the potential IRA discount on Austedo could be about 40% off the list price, UBS says.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva announces presentation of data from survey of patients taking AUSTEDO XR
- Teva preesents 10 posters from its schizophrenia medicines portfolio
- Riot, D-Wave, AmEx, Lowe’s, Teva: Stock Shake-Up!
- Teva’s emrusolmin granted U.S. FDA Fast Track designation
- Teva announces FDA approval, launch of Generic Saxenda